Human iPS Cell Detection via Stem Cell Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to identify and characterize nascent human induced pluripotent stem cells (iPS cells) amidst a heterogeneous population, hindering the definition of molecular milestones, kinetics, and underlying mechanisms of reprogramming.
Innovation Solution
The use of specific stem cell markers such as Rex1, DNMT3B, ABCG2, and other phenotypic markers to detect and stage reprogrammed cells through detectably labeled binding moieties, allowing for the identification of fully reprogrammed iPS cells and assessment of reprogramming stages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If molecular reporters are integrated into genomic loci to identify reprogrammed cells, then identification of reprogrammed mouse fibroblasts is facilitated, but there are no current methods to faithfully identify nascent human iPS cells amongst a large and heterogeneous population of fibroblasts and imperfectly reprogrammed cells
Solution Approach 1:
The patent applies parameter changes by transitioning from mouse-specific molecular reporters to a combination of human-specific stem cell markers (Nanog, Rex1, Oct4, Sox2, Tra-1-60, SSEA-4) and differentiation markers (CD13, vimentin). This parameter change in marker selection enables faithful identification of nascent human iPS cells amidst heterogeneous fibroblast populations, resolving the limitation of previous methods that worked for mouse but not human cells.
2Measurement precision
If a combination of stem cell markers and differentiation markers is used to identify fully reprogrammed iPS cells, then accurate detection and staging of reprogrammed cells is enabled, but the complexity of the detection method increases
Solution Approach 1:
The patent applies segmentation by dividing the detection system into distinct functional modules: stem cell marker detection (Nanog, Rex1, Oct4, Sox2) and differentiation marker detection (CD13, vimentin). This segmentation allows each marker to be detected independently through specific binding moieties, enabling accurate multi-parameter characterization while maintaining methodological clarity and facilitating staged identification of reprogramming progression.
Solution Approach 2:
The patent applies universality by developing a multi-functional detection system that simultaneously identifies multiple cell states (unreprogrammed, partially reprogrammed, fully reprogrammed) using a panel of markers. The same detection platform can track various stem cell markers and differentiation markers to provide comprehensive characterization of reprogramming at different stages, making the method universally applicable to human iPS cell identification.
3Loss of information
If phenotypic markers are used to stage reprogramming cells, then the kinetics and molecular milestones of reprogramming can be defined, but the heterogeneity of the cell population makes faithful identification difficult
Solution Approach 1:
The patent applies the intermediary principle by using detectably labeled binding moieties (antibodies or binding proteins) as mediators between the phenotypic markers on cell surfaces and the detection system. These binding moieties specifically recognize and bind to stem cell markers (Tra-1-60, SSEA-4) and differentiation markers (CD13, vimentin), enabling faithful identification and staging of individual cells within the heterogeneous population, thereby preserving reprogramming milestone information despite population diversity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate detection and staging of reprogrammed cells, facilitating the monitoring of the reprogramming process and screening for agents that enhance reprogramming efficiency, thereby improving the characterization and production of iPS cells.
Implementation Method 1
contacting a somatic cell induced to reprogram or its progeny with a plurality of detectably labeled binding moieties that bind at least one of Rex1, DNMT3B, and/or ABCG2
Data Source
AI summary
The methods and kits described herein are based, in part, to the discovery of a phenotype representing a fully-reprogrammed iPS cell and several reprogramming intermediates. The methods and kits described herein permit identification of fully-reprogrammed iPS cells and further permits one of skill in the art to monitor the emergence of iPS cells during the reprogramming process. The methods/kits can also be performed using real time using live cell imaging. Also described herein are methods for screening candidate reprogramming agents by monitoring the emergence of fully-reprogrammed iPS cells in the presence and absence of such an agent.